Accelerated formulation development of monoclonal antibodies (MABS) and mab-based modalities: Review of methods and tools

Journal of Biomolecular Screening

Volumn 20, Issue 4, 2015, Pages 468-483

  Razinkov, Vladimir I ^a   Treuheit, Michael J ^a   Becker, Gerald W ^a  

^a AMGEN INC   (United States)

Author keywords

design of experiment; drug development; formulation development; high throughput methods; monoclonal antibodies; quality by design

Indexed keywords

DOXORUBICIN; EXCIPIENT; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY STRUCTURE; AUTOMATION; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; COLLOID; COMPUTER ANALYSIS; COVALENT BOND; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION COEFFICIENT; DRUG FORMULATION; DRUG QUALITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; FLOW CYTOMETRY; FLUOROMETRY; GEL PERMEATION CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HYDROPHILIC INTERACTION CHROMATOGRAPHY; HYDROPHOBICITY; IMMUNOGENICITY; INFRARED SPECTROSCOPY; ION EXCHANGE CHROMATOGRAPHY; IONIC STRENGTH; LIGHT SCATTERING; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PH; PHASE SEPARATION; PRECIPITATION; PREDICTION; PREFORMULATION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN UNFOLDING; QUALITY BY DESIGN; RAMAN SPECTROMETRY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW; THERMODYNAMICS; THERMOSTABILITY; TURBIDITY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRACENTRIFUGATION; VISCOSITY; IMMUNOLOGY; MEDICINAL CHEMISTRY;

ANTIBODIES, MONOCLONAL; AUTOMATION; CHEMISTRY, PHARMACEUTICAL; HIGH-THROUGHPUT SCREENING ASSAYS;

EID: 84925761458     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114565593     Document Type: Review

References (151)

1. Reichert J. M.. Antibodies to Watch in 2014 2013. MAbs 6.: 5-14
2. List of Therapeutic Monoclonal Antibodies. http://en.wikipedia.org/wiki/List-of-therapeutic-monoclonal-antibodies
3. Carter P. J.. Potent Antibody Therapeutics by Design. Nat Rev. Immunol. 2010 ; 6: 343-357
4. Baker M.. Upping the Ante on Antibodies. Nat. Biotechnol. 2005 ; 23: 1065-1072
5. Chon J. H., Zarbis-Papastoitsis G.. Advances in the Production and Downstream Processing of Antibodies. New Biotechnol. 2011 ; 28: 458-463
6. Wang W., Singh S., Zeng D. L., et al. Antibody Structure, Instability, and Formulation. J. Pharm. Sci. 2007 ; 96: 1-26
7. Daugherty A. L., Mrsny R. J.. Formulation and Delivery Issues for Monoclonal Antibody Therapeutics. Adv. Drug Deliv. Rev. 2006 ; 58: 686-706
8. Roberts C. J. Misbehaving Proteins;. Murphy R. M. Tsai A. M., ed. New York: Springer ; 2006 :
9. Manning M. C., Chou D. K., Murphy B. M., et al. Stability of Protein Pharmaceuticals: An Update. Pharm. Res. 2010 ; 27: 544-575
10. Hawe A., Wiggenhorn M., van de, Weert M., et al. Forced Degradation of Therapeutic Proteins. J. Pharm. Sci. 2012 ; 101: 895-913
11. Vermeer A. W. P., Norde W.. The Thermal Stability of Immunoglobulin: Unfolding and Aggregation of a Multi-Domain Protein. Biophys. J. 2000 ; 78: 394-404
12. Lindman S., Xue W.-F., Szczepankiewicz O., et al. Salting the Charged Surface: pH and Salt Dependence of Protein G B1 Stability. Biophys. J. 2006 ; 90: 2911-2921
13. Cheng W., Joshi S. B., He F., et al. Comparison of High-Throughput Biophysical Methods to Identify Stabilizing Excipients for a Model IgG2 Monoclonal Antibody: Conformational Stability and Kinetic Aggregation Measurements. J. Pharm. Sci. 2012 ; 101: 1701-1720
14. Lo M.-C., Aulabaugh A., Jin G., et al. Evaluation of Fluorescence-Based Thermal Shift Assays for Hit Identification in Drug Discovery. Anal. Biochem. 2004 ; 332: 153-159
15. He F., Hogan S., Latypov R. F., et al. High Throughput Thermostability Screening of Monoclonal Antibody Formulations. J. Pharm. Sci. 2010 ; 99: 1707-1720
16. Menzen T., Friess W.. High-Throughput Melting-Temperature Analysis of a Monoclonal Antibody by Differential Scanning Fluorimetry in the Presence of Surfactants. J. Pharm. Sci. 2013 ; 102: 415-428
17. He F., Phan D. H., Hogan S., et al. Detection of IgG Aggregation by a High Throughput Method Based on Extrinsic Fluorescence. J. Pharm. Sci. 2010 ; 99: 2598-2608
18. Capelle R. G., Gurny R., Arvinte T. A.. High Throughput Protein Formulation Platform: Case Study of Salmon Calcitonin. Pharm. Res. 2009 ; 26: 118-128
19. Goldberg D. S., Bishop S. M., Shah A. U., et al. Formulation Development of Therapeutic Monoclonal Antibodies Using High-Throughput Fluorescence and Static Light Scattering Techniques: Role of Conformational and Colloidal Stability. J. Pharm. Sci. 2011 ; 100: 1306-1315
20. Wishart D. S.. Characterization of Biopharmaceuticals by NMR Spectroscopy. TrAC Trends Anal. Chem. 2013 ; 48: 96-111
21. Boulet-Audet M., Byrne B., Kazarian S. G.. High-Throughput Thermal Stability Analysis of a Monoclonal Antibody by ATR-FTIR Spectroscopic Imaging. Anal. Chem. 2014 ; 86: 9786-9793
22. Valet O., Lankers M., Adi H., et al. The Use of High Throughput Raman Microscopy for the Concurrent Size Determination and Chemical Characterization of Inhalation Particles. Resp. Drug. Del. 2010 ; 3: 763-768
23. Mahler H.-C., Müller R., Frieß W., et al. Induction and Analysis of Aggregates in a Liquid IgG1-Antibody Formulation. Eur. J. Pharm. Biopharm. 2005 ; 59: 407-417
24. Bajaj H., Sharma V. K., Badkar A., et al. Protein Structural Conformation and Not Second Virial Coefficient Relates to Long-Term Irreversible Aggregation of a Monoclonal Antibody and Ovalbumin in Solution. Pharm. Res. 2006 ; 23: 1382-1394
25. Ducry L., Stump B.. Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies. Bioconj. Chem. 2009 ; 21: 5-13
26. Guo J., Kumar S., Prashad A., et al. Assessment of Physical Stability of an Antibody Drug Conjugate by Higher Order Structure Analysis: Impact of Thiol-Maleimide Chemistry. Pharm. Res. 2014: 1-14
27. Adem Y. T., Schwarz K. A., Duenas E., et al. Auristatin Antibody Drug Conjugate Physical Instability and the Role of Drug Payload. Bioconj. Chem. 2014 ; 25: 656-666
28. McDonagh C. F., Turcott E., Westendorf L., et al. Engineered Antibody-Drug Conjugates With Defined Sites and Stoichiometries of Drug Attachment. Protein Eng. Design Selection. 2006 ; 19: 299-307
29. Rouet R., Christ D.. Bispecific Antibodies with Native Chain Structure. Nat. Biotechnol. 2014 ; 32: 136-137
30. Garber E., Demarest S. J.. A Broad Range of Fab Stabilities within a Host of Therapeutic IgGs. Biochem. Biophys. Res. Commun. 2007 ; 355: 751-757
31. Ewert S., Huber T., Honegger A., et al. Biophysical Properties of Human Antibody Variable Domains. J. Mol. Biol. 2003 ; 325: 531-553
32. Rouet R., Lowe D., Christ D.. Stability Engineering of the Human Antibody Repertoire. FEBS Lett. 2014 ; 588: 269-277
33. Boström M., Tavares F. W., Finet S., et al. Why Forces between Proteins Follow Different Hofmeister Series for pH above and below pI. Biophys. Chem. 2005 ; 117: 217-224
34. Fesinmeyer R. M., Hogan S., Saluja A., et al. Effect of Ions on Agitation and Temperature-Induced Aggregation Reactions of Antibodies. Pharm. Res.. 2009 ; 26: 903-913
35. Hiroyuki H., Arakawa T., Shiraki T.. Effect of Additives on Protein Aggregation. Curr. Pharm. Biotech. 2009 ; 10: 400-407
36. Neal B. L., Asthagiri D., Lenhoff A. M.. Molecular Origins of Osmotic Second Virial Coefficients of Proteins. Biophys. J. 1998 ; 75: 2469-2477
37. Valente J. J., Payne R. W., Manning M. C., et al. Colloidal Behavior of Proteins: Effects of the Second Virial Coefficient on Solubility, Crystallization and Aggregation of Proteins in Aqueous Solution. Curr. Pharm. Biotechnol. 2005 ; 6: 427-436
38. Li Y., Mach H., Blue J. T.. High Throughput Formulation Screening for Global Aggregation Behaviors of Three Monoclonal Antibodies. J. Pharm. Sci. 2011 ; 100: 2120-2135
39. Le Brun V., Friess W., Garidel P.. A Critical Evaluation of Self-Interaction Chromatography as a Predictive Tool for the Assessment of Protein-Protein Interactions in Protein Formulation Development: A Case Study of a Therapeutic Monoclonal Antibody. Eur. J. Pharm. Biopharm. 2010 ; 75: 16-25
40. Saito S., Hasegawa J., Kobayashi N., et al. Effects of Ionic Strength and Sugars on the Aggregation Propensity of Monoclonal Antibodies: Influence of Colloidal and Conformational Stabilities. Pharm. Res. 2013 ; 30: 1263-1280
41. Yadav S., Liu J., Shire S. J., et al. Specific Interactions in High Concentration Antibody Solutions Resulting in High Viscosity. J. Pharm. Sci. 2010 ; 99: 1152-1168
42. Saito S., Hasegawa J., Kobayashi N., et al. Behavior of Monoclonal Antibodies: Relation between the Second Virial Coefficient (B2) at Low Concentrations and Aggregation Propensity and Viscosity at High Concentrations. Pharm. Res. 2012 ; 292: 397-410
43. He F., Woods C. E., Becker G. W., et al. High-Throughput Assessment of Thermal and Colloidal Stability Parameters for Monoclonal Antibody Formulations. J. Pharm. Sci. 2011 ; 100: 5126-5141
44. Blanco M. A., Sahin E., Robinson A. S., et al. Coarse-Grained Model for Colloidal Protein Interactions, B22, and Protein Cluster Formation. J. Phys. Chem. B. 2013 ; 117: 16013-16028
45. Banks D. D., Latypov R. F., Ketchem R. R., et al. Native-State Solubility and Transfer Free Energy as Predictive Tools for Selecting Excipients to Include in Protein Formulation Development Studies. J. Pharm. Sci. 2012 ; 101: 2720-2732
46. Gibson T. J., Mccarty K., Mcfadyen I. J., et al. Application of a High-Throughput Screening Procedure with PEG-Induced Precipitation to Compare Relative Protein Solubility during Formulation Development with IgG1 Monoclonal Antibodies. J. Pharm. Sci. 2011 ; 100: 1009-1021
47. Wang Y., Latypov R. F., Lomakin A., et al. Quantitative Evaluation of Colloidal Stability of Antibody Solutions Using PEG-Induced Liquid-Liquid Phase Separation. Mol. Pharm. 2014 ; 11: 1391-1402
48. Philo J. S.. A Critical Review of Methods for Size Characterization of Non-Particulate Protein Aggregates. Curr. Pharm. Biotech. 2009 ; 10: 359-372
49. Lebowitz J., Lewis M. S., Schuck P.. Modern Analytical Ultracentrifugation in Protein Science: A Tutorial Review. Protein Sci. 2002 ; 11: 2067-2079
50. Jie W., Arakawa T., Philo J. S.. Size-Exclusion Chromatography with On-Line Light-Scattering, Absorbance, and Refractive Index Detectors for Studying Proteins and Their Interactions. Anal. Biochem. 1996 ; 240: 155-166
51. Wang Y., Lomakin A., Latypov R. F., et al. Phase Transitions in Human IgG Solutions. J. Chem. Phys. 2013 ; 139: 121904
52. Wang Y., Latypov R. F., Lomakin A., et al. Quantitative Evaluation of Colloidal Stability of Antibody Solutions Using PEG-Induced Liquid-Liquid Phase Separation. Mol. Pharm. 2014 ; 11: 1391-1402
53. Barnard J. G., Singh S., Randolph T. W., et al. Subvisible Particle Counting Provides a Sensitive Method of Detecting and Quantifying Aggregation of Monoclonal Antibody Caused by Freeze-Thawing: Insights into the Roles of Particles in the Protein Aggregation Pathway. J. Pharm. Sci. 2011 ; 100: 492-503
54. Joubert M. K., Luo Q., Nashed-Samuel Y., et al. Classification and Characterization of Therapeutic Antibody Aggregates. J. Biol. Chem. 2011 ; 286: 25118-25133
55. Singh S. K., Afonina N., Awwad M., et al. An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics. J. Pharm. Sci. 2010 ; 99: 3302-3321
56. Huang C.-T., Sharma D., Oma P., et al. Quantitation of Protein Particles in Parenteral Solutions Using Micro-Flow Imaging. J. Pharm. Sci. 2009 ; 98: 3058-3071
57. Nishi H., Mathäs R., Fürst R., et al. Label-Free Flow Cytometry Analysis of Subvisible Aggregates in Liquid IgG1 Antibody Formulations. J. Pharm. Sci. 2014 ; 103: 90-99
58. Morley J. E.. Developing Novel Therapeutic Approaches to Frailty. Curr. Pharm. Design. 2009 ; 15: 3384-3395
59. Saluja A., Crampton S., Kras E., et al. Anion Binding Mediated Precipitation of a Peptibody. Pharm. Res. 2009 ; 26: 152-160
60. Mei B., Low S. C., Krassova S., et al Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenge. Schmidt S. R., ed. Hoboken, NJ: John Wiley & Sons ; 2013 :
61. Pelletier M., Thompson J. S., Qian F., et al. Comparison of Soluble Decoy IgG Fusion Proteins of BAFF-R and BCMA as Antagonists for BAFF. J. Biol. Chem. 2003 ; 278: 33127-33133
62. Dubowchik G. M., Radia S., Mastalerz H., et al. Doxorubicin Immunoconjugates Containing Bivalent, Lysosomally-Cleavable Dipeptide Linkages. Bioorg. Med. Chem. Lett. 2002 ; 12: 1529-1532
63. King H. D., Yurgaitis D., Willner D., et al. Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains. J. Med. Chem. 2002 ; 45: 4336-4343
64. Eisenhaber B., Eisenhabe F.. Prediction of Posttranslational Modification of Proteins from Their Amino Acid Sequence. Methods Mol. Biol. 2010 ; 609: 365-384
65. Sanchez R., Riddle M., Woo J.. Prediction of Reversibly Oxidized Protein Cystein Thiols Using Protein Structure Properties. Protein Sci. 2008 ; 17: 473-481
66. Introduction to Protein Structure Prediction: Methods and Algorithms;. Rangwala H. Karypis G., ed. New York: John Wiley ; 2010 :
67. Weitzhandler M., Farnan D., Horvath J., et al. Protein Variant Separations by Cation-Exchange Chromatography on Tentacle-Type Polymeric Stationary Phases. J. Chromatogr. A. 1998 ; 828: 365-372
68. Santora L. C., Krull I. S., Grant K.. Characterization of Recombinant Human Monoclonal Tissue Necrosis Factor-α Antibody Using Cation-Exchange HPLC and Capillary Isoelectric Focusing. Anal. Biochem. 1999 ; 275: 98-108
69. Chelius D., Jing K., Lueras A., et al. Formation of Pyroglutamic Acid from N-terminal Glutamic Acid in Immunoglobulin Gamma Antibodies. Anal. Chem. 2006 ; 78: 2370-2376
70. Hsu Y.-R., Chang W.-C., Mendiaz E. A., et al. Selective Deamidation of Recombinant Human Stem Cell Factor during In Vitro Aging: Isolation and Characterization of the Aspartyl and Isoaspartyl Homodimers and Heterodimers. Biochemistry. 1998 ; 37: 2251-2262
71. del la, Guntiñas M., Wissiack R., Bordin G., et al. Determination of Haemoglobin A(1c) by Liquid Chromatography Using a New Cation-Exchange Column. J. Chromatogr. B. 2003 ; 791: 73-83
72. Gaza-Bulseco G., Faldu S., Hurkmans K.. Effect of Methionine Oxidation of a Recombinant Monoclonal Antibody on the Binding Affinity to Protein A and Protein G. J. Chromatogr. B. 2008 ; 870: 55-62
73. Ji J. A., Zhang J. A., Cheng W. Y., et al. Methionine, Tryptophan, and Histidine Oxidation in a Model Protein, PTH: Mechanisms and Stabilization. J. Pharm. Sci. 2009 ; 98: 4485-4500
74. Flatman S., Alan I., Gerard J., et al. Process Analytics for Purification of Monoclonal Antibodies. J. Chromatogr. B. 2007 ; 848: 79-87
75. Schenerman M., Sunday B. R., Kozlowski S., et al. CMC Strategy Forum Report: Analysis and Structure Characterization of Monoclonal Antibodies. BioProcess Int. 2004 ; 2: 42-52
76. Stackhouse N., Miller A. K., Himanshu S. H.. A High-Throughput UPLC Method for the Characterization of Chemical Modifications in Monoclonal Antibody Molecules. J. Pharm. Sci. 2011 ; 100: 5115-5125
77. Farnan D., Moreno G. T.. Multiproduct High-Resolution Monoclonal Antibody Charge Variant Separations by pH Gradient Ion-Exchange Chromatography. Anal. Chem. 2009 ; 81: 8846-8857
78. Chelius D., Xiao G., Nichols A. C., et al. Automated Tryptic Digestion Procedure for HPLC/MS/MS Peptide Mapping of Immunoglobulin Gamma Antibodies in Pharmaceutics. J. Pharm. Biomed. Anal. 2008 ; 47: 285-294
79. Kang S. H., Gong X., Yeung E. S.. High-Throughput Comprehensive Peptide Mapping of Proteins by Multiplexed Capillary Electrophoresis. Anal. Chem. 2000 ; 72: 3014-3021
80. Mazur M. T., Seipert R. S., Mahon D., et al. A Platform for Characterizing Therapeutic Monoclonal Antibody Breakdown Products by 2D Chromatography and Top-Down Mass Spectrometry. AAPS J. 2012 ; 14: 530-541
81. Prien J. M., Prater B. D., Qin Q., et al. Mass Spectrometric-Based Stable Isotopic 2-Aminobenzoic Acid Glycan Mapping for Rapid Screening of Biotherapeutics. Anal. Chem. 2010 ; 82: 1498-1508
82. Drachman J. G., Senter P. D.. Antibody-Drug Conjugates: The Chemistry behind Empowering Antibodies to Fight Cancer. ASH Education Program Book. 2013 ; 1: 306-331
83. Muyldermans S.. Nanobodies: Natural Single-Domain Antibodies. Ann. Rev. Biochem. 2013 ; 82: 775-797
84. Lu A., Waanders L. F., Almeida R., et al. Nanoelectrospray Peptide Mapping Revisited. Intern. J. Mass Spec. 2007 ; 268: 158-167
85. Yadav S., Laue T. M., Kalonia D. S., et al. The Influence of Charge Distribution on Self-Association and Viscosity Behavior of Monoclonal Antibody Solutions. Mol. Pharm. 2012 ; 9: 791-802
86. Connolly B. D., Petry C., Yadav S., et al. Weak Interactions Govern the Viscosity of Concentrated Antibody Solutions: High-Throughput Analysis Using the Diffusion Interaction Parameter. Biophys J. 2012 ; 103: 69-78
87. Eguchi Y., Karino T.. Measurement of Rheologic Property of Blood by a Falling Ball Blood Viscometer. Ann. Biomed. Eng. 2008 ; 36: 545-553
88. Patapoff T. W., Esue O.. Polysorbate 20 Prevents the Precipitation of a Monoclonal Antibody during Shear. Pharm. Dev. Technol. 2009 ; 14: 659-664
89. Rosencranz R., Bogen S. A.. Clinical Laboratory Measurement of Serum, Plasma, and Blood Viscosity. Am. J. Clin. Pathol. 2006 ; 125: S78 - S86
90. Jezek J., Rides M., Derham B., et al. Viscosity of Concentrated Therapeutic Protein Compositions. Adv. Drug Del. Rev. 2011 ; 63: 1107-1117
91. Du W., Klibanov A. M.. Hydrophobic Salts Markedly Diminish Viscosity of Concentrated Protein Solutions. Biotechnol. Bioeng. 2011 ; 108: 632-636
92. Yadav S., Shire S. J., Kalonia D. S.. Factors Affecting the Viscosity in High Concentration Solutions of Different Monoclonal Antibodies. J. Pharm. Sci. 2010 ; 99: 4812-4829
93. Schmitz K. An Introduction to Dynamic Light Scattering of Macromolecules;. San Diego, CA: Academic Press ; 1990 :
94. He F., Becker G. W., Litowski J. R., et al. High-Throughput Dynamic Light Scattering Method for Measuring Viscosity of Concentrated Protein Solutions. Anal. Biochem. 2010 ; 399: 141-143
95. He F., Woods C. E., Litowski J. R., et al. Effect of Sugar Molecules on the Viscosity of High Concentration Monoclonal Antibody Solutions. Pharm. Res. 2011 ; 28: 1552-1560
96. Wagner M., Reiche K., Blume A., et al. Viscosity Measurements of Antibody Solutions by Photon Correlation Spectroscopy: An Indirect Approach - Limitations and Applicability for High-Concentration Liquid Protein Solutions. Pharm. Dev. Technol. 2013 ; 18: 963-970
97. American National Standard Institute. ANSI/SBS 1-2004. 1/27/2006. http://openwetware.org/images/4/43/Microplate-dimensions.pdf
98. Majors R. E.. New Developments in Microplates for Biological Assays and Automated Sample Preparation. LC-GC Europe. 2008 ; 18: 72-76
99. Alekseychyk L., Su C., Becker G. W.. High-Throughput Screening and Stability Optimization of Anti-Streptavidin IgG1 and IgG2 Formulations. J. Biomol. Screen. 2014 ; 19: 1290-1301
100. Zhao H., Graf O., Milovic N.. Formulation Development of Antibodies Using Robotic System and High-Throughput Laboratory (HTL). J. Pharm. Sci. 2010 ; 99: 2279-2294
101. Warne N. W.. Development of High Concentration Protein Biopharmaceuticals: The Use of Platform Approaches in Formulation Development. Eur. J. Pharm. Biopharm. 2011 ; 78: 208-212
102. Low D., O'Leary R., Pujar N. S.. Future of Antibody Purification. J. Chromatogr. B. 2007 ; 848: 48-63
103. Shukla A. A., Hubbard B., Tressel T., et al. Downstream Processing of Monoclonal Antibodies - Application of Platform Approaches. J. Chromatogr. B. 2007 ; 848: 28-39
104. Makarenkov V., Zentilli P., Kevorkov D., et al. An Efficient Method for the Detection and Elimination of Systematic Error in High-Throughput Screening. Bioinformatics. 2007 ; 23: 1648-1657
105. Zhang J. H., Chung T. D., Oldenburg K. R.. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999 ; 4: 67-73
106. Wang L., Wang B., Lin Q.. Demonstration of MEMS-Based Differential Scanning Calorimetry for Determining Thermodynamic Properties of Biomolecules. Sensors Actuators B Chem. 2008 ; 134: 953-958
107. Horvath B., Mun M., Laird M. W.. Characterization of a Monoclonal Antibody Cell Culture Production Process Using a Quality by Design Approach. Mol. Biotechnol. 2010 ; 45: 203-206
108. Ng K., Rajagopalan N. Quality by Design for Biopharmaceuticals: Perspectives and Case Studies. Rathore A. S. Mhatre R., ed. Hoboken, NJ: John Wiley ; 2009 :
109. Awotwe-Otoo D., Agarabia C., Wu G. K., et al. Quality by Design: Impact of Formulation Variables and Their Interactions on Quality Attributes of a Lyophilized Monoclonal Antibody. Int. J. Pharm. 2012 ; 438: 167-175
110. He F., Woods C. E., Becker G. W., et al. High-Throughput Assessment of Thermal and Colloidal Stability Parameters for Monoclonal Antibody Formulations. J. Pharm. Sci. 2011 ; 100: 5126-5141
111. Rubin J., Linden L., Coco W. M., et al. Salt-Induced Aggregation of a Monoclonal Human Immunoglobulin G1. J. Pharm. Sci. 2013 ; 102: 377-386
112. Schmit J. D., He F., Mishra S., et al. Entanglement Model of Antibody Viscosity. J. Phys. Chem. B. 2014 ; 118: 5044-5049
113. He F., Woods C. E., Trilisky E., et al. Screening of Monoclonal Antibody Formulations Based on High-Throughput Thermostability and Viscosity Measurements: Design of Experiment and Statistical Analysis. J. Pharm. Sci. 2011 ; 100: 1330-1340
114. Kalonia C., Kumru O. S., Kim J. H., et al. Radar Chart Array Analysis to Visualize Effects of Formulation Variables on IgG1 Particle Formation as Measured by Multiple Analytical Techniques. J. Pharm. Sci. 2013 ; 102: 4256-4267
115. Harn N., Allan C., Oliver C., et al. Highly Concentrated Monoclonal Antibody Solutions: Direct Analysis of Physical Structure and Thermal Stability. J. Pharm. Sci. 2007 ; 96: 532-546
116. Kim J. H., Iyer V., Joshi S. B., et al. Improved Data Visualization Techniques for Analyzing Macromolecule Structural Changes. Protein Sci. 2012 ; 21: 1540-1553
117. Ramsey J. D., Gill M. L., Kamerzell T. J., et al. Using Empirical Phase Diagrams to Understand the Role of Intramolecular Dynamics in Immunoglobulin G Stability. J. Pharm. Sci. 2009 ; 98: 2432-2447
118. Bhambhani A., Kissmann J. M., Joshi S. B., et al. Formulation Design and High-throughput Excipient Selection Based on Structural Integrity and Conformational Stability of Dilute and Highly Concentrated IgG1 Monoclonal Antibody Solutions. J. Pharm. Sci. 2012 ; 101: 1120-1135
119. Alsenaidy M. A., Kim J. H., Majumdar R., et al. High-Throughput Biophysical Analysis and Data Visualization of Conformational Stability of an IgG1 Monoclonal Antibody after Deglycosylation. J. Pharm. Sci. 2013 ; 102: 3942-3956
120. Wakankar A. A., Borchardt R. T., Eigenbrot C., et al. Aspartate Isomerization in the Complementarity-Determining Regions of Two Closely Related Monoclonal Antibodies. Biochemistry. 2007 ; 46: 1534-1544
121. Aswad D. W., Paranandi M. V., Schurter B. T.. Isoaspartate in Peptides and Proteins: Formation, Significance, and Analysis. J. Pharm. Biomed. Anal. 2000 ; 21: 1129-1136
122. Luo Y., Lu Z., Raso S. W., et al. Dimers and Multimers of Monoclonal IgG1 Exhibit Higher In Vitro Binding Affinities to Fcγ Receptors. MAbs. 2009 ; 1: 491-504
123. Gao S. X., Zhang Y., Stansberry-Perkins K., et al. Fragmentation of a Highly Purified Monoclonal Antibody Attributed to Residual CHO Cell Protease Activity. Biotechnol. Bioeng. 2011 ; 108: 977-982
124. Hermeling S., Crommelin D. J., Schellekens H., et al. Structure-Immunogenicity Relationships of Therapeutic Proteins. Pharm. Res. 2004 ; 21: 897-903
125. Nagata K., Randall A., Baldi P.. Incorporating Post-Translational Modifications and Unnatural Amino Acids into High-Throughput Modeling of Protein Structures. Bioinformatics. 2014 ; 30: 1681-1689
126. Xu Y., Wang X., Wang Y., et al. Prediction of Posttranslational Modification Sites from Amino Acid Sequences with Kernel Methods. J. Theor. Biol. 2014 ; 344: 78-87
127. Woodsmith J., Stelzl U.. Studying Post-Translational Modifications with Protein Interaction Networks. Curr. Opin. Struct. Biol. 2014 ; 24: 34-44
128. Blom N., Sicheritz-Pontén T., Gupta R., et al. Prediction of Post-Translational Glycosylation and Phosphorylation of Proteins from the Amino Acid Sequence. Proteomics. 2004 ; 4: 1633-1649
129. Lauer T. M., Agrawal N. J., Chennamsetty N., et al. Developability Index: A Rapid In Silico Tool for the Screening of Antibody Aggregation Propensity. J. Pharm. Sci. 2012 ; 101: 102-115
130. Rouet R., Lowe D., Christ D.. Stability Engineering of the Human Antibody Repertoire. FEBS Lett. 2014 ; 588: 269-277
131. Walsh I., Seno F., Tosatto S. C., et al. PASTA 2.0: An Improved Server for Protein Aggregation Prediction. Nucl. Ac. Res. 2014 ; 42: W301 - W307
132. Thangakani A. M., Kumar S., Nagarajan R., et al. GAP: Towards Almost 100 Percent Prediction for β-Strand-Mediated Aggregating Peptides with Distinct Morphologies. Bioinformatics. 2014 ; 30: 1983-1990
133. Costanzo J. A., O'Brien C. J., Tiller K., et al. Conformational Stability as a Design Target to Control Protein Aggregation. Protein Eng. Des. Sel. 2014 ; 27: 157-167
134. Chennamsetty N., Voynov V., Kayser V., et al. Design of Therapeutic Proteins with Enhanced Stability. Proc. Natl. Acad. Sci. U. S. A. 2009 ; 106: 11937-11942
135. Brunsteiner M., Flock M., Nidetzky B.. Structure Based Descriptors for the Estimation of Colloidal Interactions and Protein Aggregation Propensities. PLoS One. 2013 ; 8: e59797
136. Webster S.. Predicting Long-Term Storage Stability of Therapeutic Proteins. Pharm. Tech. 2013 ; 37: 42-48
137. Wang Y., Latypov R. F., Lomakin A., et al. Quantitative Evaluation of Colloidal Stability of Antibody Solutions Using PEG-Induced Liquid-Liquid Phase Separation. Mol. Pharm. 2014 ; 11: 1391-1402
138. Jacobs W. M., Oxtoby D. W., Frenkel D.. Phase Separation in Solutions with Specific and Nonspecific Interactions. J. Chem. Phys. 2014 ; 140: 204109
139. Li L., Kumar S., Buck P., et al. Concentration Dependent Viscosity of Monoclonal Antibody Solutions: Explaining Experimental Behavior in Terms of Molecular Properties. Pharm. Res. 2014 ; 31: 3161-3178
140. Singh S. N., Yadav S., Shire S. J.. Dipole-Dipole Interaction in Antibody Solutions: Correlation with Viscosity Behavior at High Concentration. Pharm. Res. 2014 ; 31: 2549-2558
141. Seabrook S. A., Newman J.. High-Throughput Thermal Scanning for Protein Stability: Making a Good Technique More Robust. ACS Comb. Sci. 2013 ; 15: 387-392
142. Menzen T., Friess W.. Temperature-Ramped Studies on the Aggregation, Unfolding, and Interaction of a Therapeutic Monoclonal Antibody. J. Pharm. Sci. 2014 ; 103: 445-455
143. Wyatt P. J.. Light Scattering and the Absolute Characterization of Macromolecules. Anal. Chim. Act. 1993 ; 272: 1-40
144. Wei Z., McEvoy M., Razinkov V., et al. Biophysical Characterization of Influenza Virus Subpopulations Using Field Flow Fractionation and Multiangle Light Scattering: Correlation of Particle Counts, Size Distribution and Infectivity. J. Virol. Method. 2007 ; 144: 122-132
145. McEvoy M., Razinkov V, Wei Z.. Improved Particle Counting and Size Distribution Determination of Aggregated Virus Populations by Asymmetric Flow Field-Flow Fractionation and Multiangle Light Scattering Techniques. Biotech. Prog. 2010 ; 27: 547-554
146. Gibson T. J., Mccarty K., Mcfadyen I. J., et al. Application of a High-Throughput Screening Procedure with PEG-Induced Precipitation to Compare Relative Protein Solubility during Formulation Development with IgG1 Monoclonal Antibodies. J. Pharm. Sci. 2011 ; 100: 1009-1021
147. Warne N. W.. Development of High Concentration Protein Biopharmaceuticals: The Use of Platform Approaches in Formulation Development. Eur. J. Pharm. Biopharm. 2011 ; 78: 208-212
148. Cao W., Piedmonte D. M., Ricci M. S., et al Therapeutic Fc-Fusion Proteins. Chamow S. M. Ryll T. Lowman H. B. Farson D., ed. Hoboken, NJ: John Wiley ; 2013 :
149. Mueller M., Loh M. Q., Tscheliessnig R., et al. Liquid Formulations for Stabilizing IgMs during Physical Stress and Long-Term Storage. Pharm. Res. 2013 ; 30: 735-750
150. Yang X., Ambrogelly A.. Enlarging the Repertoire of Therapeutic Monoclonal Antibodies Platforms: Domesticating Half Molecule Exchange to Produce Stable IgG4 and IgG1 Bispecific Antibodies. Curr. Opin. Biotech. 2014 ; 30: 225-229
151. Harris R. J., Shire S. J., Winter C.. Commercial Manufacturing Scale Formulation and Analytical Characterization of Therapeutic Recombinant Antibodies. Drug Dev. Res. 2004 ; 61: 137-154